
    
      In this study, we will evaluate the efficacy and safety of TKI258(Dovitinib) monotherapy as a
      salvage chemotherapy after failure of standard first or second-line chemotherapy in
      metastatic or unresectable gastric cancer harboring FGFR2 amplification.
    
  